Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Linagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | FAP | Q12884 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | POU2F2 | P09086 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | POU2F1 | P14859 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linagliptin SCHEMBL29359185 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL195962 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL28983978 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL17124941 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL637238 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL16467827 | 0.99 | DPP4 (0.98) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL16467826 | 0.99 | DPP4 (0.98) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL1771687 | 0.93 | DPP4 (0.88) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL1771688 | 0.93 | DPP4 (0.88) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL639186 | 0.93 | DPP4 (0.87) | DPP4FAPCHRM1POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6441 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-26 | — | — | US | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731196-A1 | A MONOLITHIC TABLET COMPOSITION COMPRISING LINAGLIPTIN & METFORMIN | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi (TR) | 2026-04-29 | — | — | EP | claimed |
| EP-4727528-A1 | A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2026-04-22 | — | — | EP | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| EP-3801539-B1 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF LINAGLIPTIN | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2026-04-01 | — | — | EP | claimed |
| WO-2009147125-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | claimed |
| WO-2009121945-A2 | NEW FORMULATIONS, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | WO | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022010-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022008-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | claimed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | claimed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | claimed |
| US-20070259900-A1 | POLYMORPHS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | claimed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | claimed |